Ambeed.cn

首页 / 抑制剂/激动剂 / 代谢酶 / Factor Xa / Rivaroxaban

利伐沙班 /Rivaroxaban {[allProObj[0].p_purity_real_show]}

货号:A454849 同义名: BAY 59-7939 Ambeed 开学季,买赠积分,赢豪礼

Rivaroxaban is an inhibitor of factor Xa (FXa) with IC50 of 0.7 nM and Ki of 0.4 nM which developed for the treatment of thrombotic disease.

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Rivaroxaban 化学结构 CAS号:366789-02-8
Rivaroxaban 化学结构
CAS号:366789-02-8
Rivaroxaban 3D分子结构
CAS号:366789-02-8
Rivaroxaban 化学结构 CAS号:366789-02-8
Rivaroxaban 3D分子结构 CAS号:366789-02-8
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Rivaroxaban 纯度/质量文件 产品仅供科研

货号:A454849 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

JACS Au, 2024. Ambeed. [ A148168 ]
JMC, 2024. Ambeed. [ A187643 ]
JMC, 2024. Ambeed. [ A341145 , A633512 , A607865 , A167774 ]
Biomacromolecules, 2024. Ambeed. [ A110759 ]
Biomacromolecules, 2024. Ambeed. [ A203543 ]
更多 >
产品名称 Factor Xa 其他靶点 纯度
Rivaroxaban ++

Factor Xa, IC50: 0.7 nM

{[allProObj[0].p_purity_real_show]}
Apixaban ++++

Factor Xa (human), Ki: 0.08 nM

Factor Xa (rabbit), Ki: 0.17 nM

{[allProObj[0].p_purity_real_show]}
Edoxaban tosylate monohydrate +++

Factor Xa, Ki: 0.561 nM

{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Rivaroxaban 生物活性

靶点
  • Factor Xa

    Factor Xa, IC50:0.7 nM

描述 The activated serine protease Factor Xa (FXa), activated by both the intrinsic and the extrinsic pathways, plays a central role in the blood coagulation cascade. FXa catalyzes the conversion of prothrombin tothrombin through the prothrombinase complex[3]. Rivaroxaban, also called BAY 59-7939, is an inhibitor of FXa with IC50 of 0.7 nM and Ki of 0.4 nM which is under clinical development for the treatment of thrombotic disease[3]. Rivaroxaban (15, 30, or 60 ng/mL) inhibited thrombin generation in a concentration-dependent manner and the effect was enhanced with ticagrelor (1.0 µg/mL) and ticagrelor plus acetylsalicylic acid (100 µg/mL). Rivaroxaban (0.01, 0.03, or 0.1 mg/kg) also dose-dependently reduced thrombus formation in arteriovenous shunt model in rats[4]. Oral rivaroxaban (2.5 mg twice-daily [bid] and 5 mg bid) reduced mortality and morbidity in patients with acute coronary syndrome, when combined with antiplatelets[5].
作用机制 Rivaroxaban forms two hydrogen bonds to Gly219 of Factor Xa.

Rivaroxaban 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02248610 - Recruiting November 2019 United Kingdom ... 展开 >> Basingstoke Hospital Not yet recruiting Basingstoke, United Kingdom Bournemouth Hospital Not yet recruiting Bournemouth, United Kingdom Kings College Hospital NHS Foundation Trust Recruiting London, United Kingdom, SE5 9RS Contact: Kathryn Lang, MBBS, MRCP(UK)    02032999000 ext 31421    kathryn.lang@nhs.net    Contact: Rosalind Wilmott    02032993000    rosalind.wilmott@nhs.net    Salisbury Hospital Not yet recruiting Salisbury, United Kingdom 收起 <<
NCT02549963 Atrial Fibrillation ... 展开 >> Stroke 收起 << Phase 4 Unknown - China, Beijing ... 展开 >> Beijing Anzhen Hospital Not yet recruiting Beijing, Beijing, China, 100029 Contact: Changsheng Ma, M.D. Ph.D.          China, Guangdong Nanfang Hospital Not yet recruiting Guangzhou, Guangdong, China, 510000 Contact: Xiaobo Huang, M.D. Ph.D.          The first Affiliated Hospital of Guangzhou medical University Not yet recruiting Guangzhou, Guangdong, China, 510000 Contact: Wei Wang, M.D.          The first affiliated hospital of Jinan university Not yet recruiting Guangzhou, Guangdong, China, 510000 Contact: Aidong Zhang, M.D. Ph.D.          The First Affiliated Hospital of Sun Yat-sen University Not yet recruiting Guangzhou, Guangdong, China, 510000 Contact: Yugang Dong, M.D. Ph.D.          The second Affiliated Hospital of Guangzhou medical University Not yet recruiting Guangzhou, Guangdong, China, 510000 Contact: Shiming Liu, M.D. Ph.D.          Guangdong Cardiovascular Institute, Guangdong General Hospital Guangzhou, Guangdong, China, 510080 The Affiliated Hospital of Guangdong Medical College Not yet recruiting Zhanjiang, Guangdong, China, 524000 Contact: Chan Chen, M.D. Ph.D.          China, Hubei Wuhan Asia Heart Hospital Not yet recruiting Wuhan, Hubei, China, 430000 Contact: Su Xi, M.D. Ph.D. 收起 <<
NCT02123524 Symptomatic Superficial Vein T... 展开 >>hrombosis 收起 << Phase 3 Completed - Canada, Alberta ... 展开 >> University of Alberta Hospital Edmonton, Alberta, Canada, T6G 2B7 Canada, Ontario Hamilton General Hospital Hamilton, Ontario, Canada, L8L2X2 St Josephs Healthcare Hamilton, Ontario, Canada, L8N4A6 Juravinski Hospital Hamilton, Ontario, Canada, L8V1C3 McMaster Hospital Hamilton, Ontario, Canada The Ottawa Hospital Ottawa, Ontario, Canada, K1H8L6 Canada, Quebec Hopital Maisonneuve - Rosemount Montreal, Quebec, Canada, H1T 2M4 Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Hopital Sacre Coeur Montreal, Quebec, Canada, H4J1C5 Montreal General Hospital Montreal, Quebec, Canada St Mary's Hospital Montreal, Quebec, Canada 收起 <<

Rivaroxaban 参考文献

[1]Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, Sandmann S. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther. 2011 Jul;338(1):372-80.

[2]Perzborn E, Strassburger J, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor. J Thromb Haemost. 2005 Mar;3(3):514-21.

[3]Roehrig S, Straub A, Pohlmann J, Lampe T, Pernerstorfer J, Schlemmer KH, Reinemer P, Perzborn E. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem. 2005 Sep 22;48(19):5900-8. doi: 10.1021/jm050101d. PMID: 16161994.

[4]Effects of Rivaroxaban on Platelet Activation and Platelet–Coagulation Pathway Interaction: In Vitro and In Vivo Studies

[5]Bauersachs R, Zannad F. Rivaroxaban: A New Treatment Paradigm in the Setting of Vascular Protection? Thromb Haemost. 2018 May;118(S 01):S12-S22. doi: 10.1055/s-0038-1636530. Epub 2018 Mar 22. PMID: 29566413.

Rivaroxaban 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.29mL

0.46mL

0.23mL

11.47mL

2.29mL

1.15mL

22.94mL

4.59mL

2.29mL

Rivaroxaban 技术信息

CAS号366789-02-8
分子式C19H18ClN3O5S
分子量 435.881
别名 BAY 59-7939
运输蓝冰
存储条件

粉末 Inert atmosphere,2-8°C

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 50 mg/mL(114.71 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方

0.5% methylcellulose+0.2% Tween 80+water 5 mg/mL suspension

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。